Mr. Welborn is Senior Advisor, Stadium Capital Management, LLC, an investment advisory firm. His extensive investment and advisory background includes work with The Beacon Group, LLC, which is now part of J.P. Morgan Chase & Co. He also served on the Boards of Intermountain Community Bancorp, Panhandle State Bank, Inc., and Ascena Retail Group, Inc. and was a Board observer at West Coast Bancorp. Mr. Welborn holds a BS degree in Commerce, with concentrations in Finance and Accounting, from the McIntire School of Commerce at the University of Virginia.

Mr. Millian is a pharmaceutical executive. Prior to joining HLS Therapeutics as CEO, he served as the Chief Operating Officer at Corbus Pharmaceutical, contributing its organizational transformation. Mr. Millian held several commercial leadership positions at EMD Serono, where he led strategic direction and drove operating results for several important franchises. MBA as Vice President, Commercial, at Vertex Pharmaceuticals, he helped design and build commercial infrastructure, organizational capabilities, and go-to-market strategies. Early in his career, he held marketing leadership roles for several blockbuster brands at both Pfizer Inc. and Sanofi. Mr. Millian earned an MBA from New York University and a Finance degree from the Wharton School, University of Pennsylvania.

Ms. Brege is Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. She brings extensive US public company and life sciences experience in as both a C-level executive and Board member. Ms. Brege currently serves on the Boards of Acadia Pharmaceuticals (NASDAQ:ACAD), Aratana Therapeutics (NASDAQ:PETX), Pacira Pharmaceuticals (NASDAQ:PCRX), Portola Pharmaceuticals (NASDAQ:PTLA), and Dynavax Technologies (NASDAQ:DVAX).

Mr. Hill is Global Head of Technology, Data and Security Ontario Municipal Employees Retirement System Administration Corporation (“OMERS”). He has more than 30 years of experience in business management, risk management, technology, finance, and accounting. Mr. Hill joined OMERS in 2011 as EVP & Chief Auditor, and in 2015 was appointed to serve as OMERS first Chief Risk Officer. He moved into his current role in 2023. Mr. Hill previously worked at PriceWaterhouseCoopers for 22 years, the last 10 of which as a Partner specializing in auditing complex public and private companies in a variety of sectors, including pharmaceuticals.

Ms. Beauchamp is corporate director with over 30 years of health care experience in corporate and non-profit organizations, including executive positions at Bayer Healthcare (Canada and Global) and Sanofi Canada. Ms. Beauchamp serves on the Boards of Aurora Cannabis Inc. (TSX:ACB) (“Aurora”), as Chair of its Nominating and Corporate Governance Committee and a member of its Human Resources and Compensation Committee, Extendicare Inc. (TSX:EXE), as a member of the Investment Committee and the Quality and Risk Committee, and Dialogue Health Technologies Inc. (TSX:CARE), a leading telehealth service. Formerly, Ms. Beauchamp served on the Board of MedReleaf Corp., prior to its acquisition by Aurora. Ms. Beauchamp also serves as a member of the National Research Council of Canada, is on the Board of the Ontario Caregiver Organization, and is a Regional Ambassador with Women Get on Board. Ms. Beauchamp has completed the University of Toronto’s Rotman School of Management Directors Education Program (ICD.D) and holds a Bachelor of Business Administration in Marketing from Bishop’s University.

Dr. Dempsey is a partner at MVM Partners. Kyle joined MVM Partners, a healthcare focused private equity fund based in Boston, Massachusetts and London, UK, in 2017. Prior to MVM, he was a consultant at Bain & Company, working mainly in the healthcare practice to support medical device and healthcare provider clients. During his undergraduate and graduate education, Kyle was a prolific researcher and writer, publishing peer-reviewed papers on topics ranging genetics to orthopedic surgery outcomes. Kyle completed MD studies at Harvard Medical School and MBA studies at Harvard Business School. He also holds an AB in biochemistry from Bowdoin College. Kyle is a Board Director of Optinose, Inc. (NASDAQ:OPTN), and GT Medical Technologies, Inc. and he is also an observer on the Board of MDxHealth SA (NASDAQ:MDXH).

Mr. Roy is a healthcare industry consultant with 30 years of experience with multinational corporations and as an entrepreneur. He is a former Partner and Executive Vice President of the Healthcare division at TANK Worldwide Inc. until it was acquired by WPP plc in June 2022. Prior to joining TANK in 2013, Mr. Roy spent more than 20 years in the pharmaceutical industry, including as Vice President of Marketing for Pfizer in Canada from 2008 to 2013. He has broad experience working on projects in Canada, the United States, Europe, and Asia. Mr. Roy holds a Bachelor of Chemical Engineering from University of Sherbrooke.

Mr. Hanna is a finance executive with 20+ years working with C-level Executives and Board members of public companies. Before joining HLS Therapeutics, he was CFO at Inca Networks Inc. During his 10-year tenure as CFO of Vecima Networks Inc. (TSX:VCM) he held operational P&L responsibilities, monetizing non-core assets and acquiring strategic assets to grow their business. Earlier, Mr. Hanna held senior financial positions with The Westaim Corporation (TSX:WED), including VP Corporate Development with Westaim Biomedical Corp. He holds an MBA from the University of British Columbia, a BSc from the University of Victoria. Mr. Hanna is also designated accountant (CPA, CGA) and experienced corporate Board Member for venture-backed technology companies, including Vector 12 and LTG Lasertech.